22536-63-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-4-methoxypyrimidine is used as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
This chemical compound is also used as an intermediate in the production of agrochemicals, specifically herbicides and fungicides. Its reactivity and versatility contribute to the development of effective and targeted agricultural products.

InChI:InChI=1/C5H5ClN2O/c1-9-4-2-3-7-5(6)8-4/h2-3H,1H3

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 865-33-8 potassium methanolate 

Downstream Products

• 6104-41-2 4-methoxypyrimidine 
• 89181-80-6 (4-methoxy-pyrimidin-2-yl)-hydrazine 
• 132331-26-1 5-(2-chloro-4-methoxypyrimidinyl)-1-phenylmethanol 
• 152696-75-8 2-((2R,3S)-3-Benzyloxy-5-phenylsulfanyl-tetrahydro-furan-2-ylmethoxy)-4-methoxy-pyrimidine 
• 2001-93-6 2,4-dithiouracil 
• 39030-96-1 2-fluoro-4-methoxy-pyrimidine 
• 204990-39-6 2-((2R,3S)-3-Benzyloxy-6-phenylsulfanyl-tetrahydro-pyran-2-ylmethoxy)-4-methoxy-pyrimidine 
• 204990-47-6 4-Methoxy-2-[(2R,3S)-3-(4-methoxy-benzyloxy)-6-phenylsulfanyl-tetrahydro-pyran-2-ylmethoxy]-pyrimidine 
• 220222-91-3 [(2S,3S)-2-(4-Methoxy-pyrimidin-2-yloxymethyl)-5-phenylsulfanyl-tetrahydro-furan-3-ylmethyl]-phosphonic acid diethyl ester 
• 915774-30-0 2-chloro-5-((4-methoxypyrimidin-2-yl)amino)phenol 
• 33630-20-5 2-phenyl-4-methoxypyrimidine 
• 55745-88-5 4-methoxy-2-(1-piperazinyl)-pyrimidine 
• 894400-12-5 2-(4-iodophenoxy)-5-methoxypyrimidine 
• 894400-82-9 N-(4-iodophenyl)-4-methoxypyrimidin-2-amine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs

A novel series of 3-benzyloxy-linked pyrimidinylphenylamine derivatives (8a-8s) was designed, synthesized and evaluated for their in vitro anti-HIV activity in MT-4 cell cultures. Most of the compounds inhibited wild-type (wt) HIV-1 replication in the lower micromolar concentration range (EC50 = 0.05-35 μM) with high selectivity index (SI) values (ranged from 10 to >4870). In particular, 8h and 8g displayed excellent antiretroviral activity against wt HIV-1 with low cytotoxicity (EC50 = 0.07 μM, CC 50 >347 μM, SI >4870; EC50 = 0.05 μM, CC 50 = 42 μM, SI = 777, respectively), comparable to that of the marked drug nevirapine (EC50 = 0.113 μM, CC50 >15 μM, SI >133). In order to confirm the binding target, 8h was selected to perform the anti-HIV-1 RT assay. Additionally, preliminary structure activity relationship (SAR) analysis and molecular docking studies of newly synthesized compounds were also discussed, as well as the predicted physicochemical properties.

BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their production and compounds of formula (I) for use in treating a disease responsive to the inhibition of Bruton's tyrosine.

Pyrimidine heterocyclic compounds, pyrimidine heterocyclic compound salts, and preparation method and application thereof

The invention provides pyrimidine heterocyclic compounds, pyrimidine heterocyclic compound salts, and a preparation method and application thereof. According to the pyrimidine heterocyclic compounds provided by the invention, specific Rq is selected, so that the obtained compounds have favorable drug resistance and long half life when being used as the medicine for treating or preventing HIV. The compounds have the advantages of high activity, low toxicity and high stability.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

PROCESS FOR RILPIVIRINE

The present invention provides a novel process for the preparation of 4-(4-hydroxypyrimidin-2-ylamino)benzonitrile. The present invention also provides a novel process for the preparation of 4-iodo-2,6-dimethyl benzenamine. The present invention further provides an improved process for the preparation of rilpivirine. The present invention further provides a tosylate salt of rilpivirine, process for its preparation and pharmaceutical compositions comprising it.

RILPIVIRINE HYDROCHLORIDE

The present invention provides a novel process for the preparation of rilpivirine. The present invention also provides a novel process for the preparation of rilpivirine hydrochloride. The present invention further provides a rilpivirine hydrochloride monohydrate, process for its preparation and pharmaceutical compositions comprising it.

Structural tuning of ancillary chelate in tri-carboxyterpyridine Ru(ii) sensitizers for dye sensitized solar cells

Three distinct classes of ancillary chelates, namely: 2-(3- trifluoromethylpyrazol-5-yl)-6-(3-trifluoromethylphenyl)pyridine (L3, H 2pzppy), 4-(3-trifluoromethylpyrazol-5-yl)-2-(3-trifluoromethyl) phenylpyrimidine (L5, H2pzppm) and 4-(6-(3-trifluoromethylpyrazol-5- yl)pyridin-2-yl)-2-trifluoromethylpyrimidine (L6, H2pzpypm), which showed an identical skeletal topology, but with the more electronegative nitrogen atom replacing the isoelectronic methine group at the selected skeletal position, were obtained to investigate the photophysical and electrochemical properties and hence the associated Ru(ii) sensitizers based DSCs. To increase the optical absorptivity we also strategically added thiophene (thienyl) or 3,4-ethylenedioxythiophene (EDOT) appendages to L6, for boosting the short-circuit photocurrent (JSC) and the overall efficiency (η) of the fabricated DSC devices. Under AM 1.5G illumination, the best sensitizer showed performance data of JSC = 18.11 mA cm-2, V OC = 0.66 V, FF = 0.729 and η = 8.72%, and a good cell stability at 60 °C for 1000 hours, being only decreased by ～5% in the η value.

RILPIVIRINE HYDROCHLORIDE

As used herein the term "room temperature" refers to a temperature of about 25°C to about 35°C. According to one aspect of the present invention, there IS provided a novel process for the preparation of rilpivirine, which comprises: a) condensing the (E)-3-( 4-amino-3,5-dimethylphenyl)acrylonitrile hydrochloride with 4-( 4-chloropyrimidin-2-ylamino )benzonitrile m the presence of Nmethylpyrrolidone; b) heating the contents obtained in step (a) at about 75 to 95°C to obtain a solution; c) cooling the solution obtained in step (b) at below 35°C; d) adding water to the reaction mass; and e) isolating rilpivirine. The reaction in step (b) may preferably be heated to 100 to 110°C. Step (c) may preferably be carried out at room temperature. Rilpivirine may be isolated in step (e) by the methods known such as Filtration or centrifugation.

PROCESS FOR RILPIVIRINE

The present invention provides a novel process for the preparation of 4-(4-hydroxypyrimidin-2-ylamino)benzonitrile. The present invention also provides a novel process for the preparation of 4-iodo-2,6-dimethyl benzenamine. The present invention further provides an improved process for the preparation of rilpivirine. The present invention further provides a tosylate salt of rilpivirine, process for its preparation and pharmaceutical compositions comprising it.

10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE

A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).